MondegarAI
SR ONE CAPITAL MANAGEMENT, LP

Q1 2026 · 13F-HR

SR ONE CAPITAL MANAGEMENT, LPholdings as filed

Filed 2026-05-14 · accession 0001193125-26-224136

$915.4M
Reported value
14
Positions
2026-03-31
Period end
View analyzed profile →PRO

The Brief · SR ONE CAPITAL MANAGEMENT, LP · Q1 2026

AI · grounded in 13F

SR ONE CAPITAL MANAGEMENT, LP established a new position in Veradermics, Inc. MANE valued at $151.7M. This addition represents the fund's only change to its portfolio this period. The fund now manages 14 positions with total assets under management of $915.4M.

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
03940C100ACLXGBXArcellx, Inc.$269.4M29.4%2,346,630CommonSOLE
922967104MANEVeradermics, Inc.$151.7M16.6%2,401,868CommonSOLE
98937L105ZBIOZenas BioPharma, Inc$98.5M10.8%5,037,854CommonSOLE
H17182108CRSPCRISPR Therapeutics AG$97.0M10.6%2,038,763CommonSOLE
25056L103DSGNDesign Therapeutics, Inc.$69.4M7.59%6,526,476CommonSOLE
68622P109ORICORIC Pharmaceuticals, Inc.$58.5M6.39%4,514,929CommonSOLE
022307102ALMSAlumis Inc.$43.2M4.72%1,959,896CommonSOLE
603170101MLYSMineralys Therapeutics Inc.$42.4M4.63%1,563,966CommonSOLE
82835W108SPRYARS Pharmaceuticals, Inc.$32.2M3.52%4,012,903CommonSOLE
687604108ORKAOruka Therapeutics, Inc$21.1M2.31%430,330CommonSOLE
H5870P102OCSOculis Holding AG$17.0M1.86%641,022CommonSOLE
65487U108NKTXNkarta, Inc.$7.0M0.77%3,333,333CommonSOLE
29286M105enGene Holdings Inc.$5.1M0.56%747,750CommonSOLE
90400D108RAREUltragenyx Pharmaceutical Inc.$2.9M0.32%137,753CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.